Related references
Note: Only part of the references are listed.Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review
Luca Sala et al.
LUNG CANCER (2020)
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma
Takayuki Kishikawa et al.
THORACIC CANCER (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis
Lilan Yi et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Rapid drop in blood platelet count and increase in creatinine in non-small cell lung cancer (NSCLC) patients treated with osimertinib.
Inger Johanne Zwicky Eide et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety of osimertinib in EGFR-mutated non-small cell lung cancer
Laura Mezquita et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer
Hiroaki Ogata et al.
Journal of Thoracic Oncology (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
Xin Gao et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Share Paper
